Open AccessDrugs associated with drug-induced interstitial lung diseases
Author(s) -
О Д Остроумова,
А. И. Листратов,
А. И. Кочетков,
Д. А. Сычёв
Publication year - 2021
Publication title -
kačestvennaâ kliničeskaâ praktika
Language(s) - English
Resource type - Journals
eISSN - 2618-8473
pISSN - 2588-0519
DOI - 10.37489/2588-0519-2021-2-39-51
Subject(s) - medicine , interstitial lung disease , drug , disease , lung , population , respiratory tract , etiology , medical prescription , intensive care medicine , pharmacology , respiratory system , environmental health
Interstitial lesion is one of the causes of respiratory failure. Drugs are a modifiable etiological factor of lung damage. Medications most commonly associated with drug-induced interstitial lung disease include antineoplastic drugs, disease-modifying anti-rheumatic drugs and amiodarone. According to the latest literature data, the previously described link between anti-rheumatic drugs and interstitial lung diseases is very inconsistent. It may even be a protective effect of this group of drugs on the lung tissue. The relationship between statin use and interstitial lesions is also complex and not fully understood. It is necessary to carefully assess the appearance of respiratory tract complaints in patients taking statins as in other groups of patients. Prescription of additional diagnostic methods is necessary to close monitoring and prevention the toxic effect of these drugs. These actions, as well as the potential prescription of steroid therapy and change in the underlying disease treatment approaches, are an important factor in reducing the incidence of respiratory failure in the population.